BFRI
Biofrontera Inc
NASDAQ · Pharmaceuticals
$0.82
-0.02 (-2.02%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.84M | 1.67M | 1.59M |
| Net Income | 546.1K | 470.0K | 528.6K |
| EPS | — | — | — |
| Profit Margin | 29.7% | 28.1% | 33.2% |
| Rev Growth | +2.3% | +24.3% | +24.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 874.4K | 868.4K | 1.11M |
| Total Equity | 6.11M | 5.54M | 6.06M |
| D/E Ratio | 0.14 | 0.16 | 0.18 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 946.1K | 856.8K | 789.7K |
| Free Cash Flow | 614.9K | 585.2K | 384.5K |